< 生产厂家价格 >

托拉塞米

托拉塞米用途

Torsemide是吡啶磺酰脲类袢利尿剂。

点击显示

托拉塞米作用

强效利尿药作用于髓襻升枝粗段髓质部，抑制氯的主动重吸收，随之抑制了钠的重吸收，而发挥强大的利尿作用。

点击显示

托拉塞米名称

[ CAS 号 ]:
56211-40-6

[ 中文名 ]:
托拉塞米

[ 英文名 ]:
Torsemide

[中文别名 ]:

花青素提取物

[英文别名 ]:

Unat
LUPLAC
EINECS 200-659-6
Toradiur
Demadex
Torem
JDL-464
MFCD00866166
GJ-1090
AC-4464

托拉塞米生物活性

[ 描述 ]:

Torsemide是吡啶磺酰脲类袢利尿剂。

[ 相关类别 ]:

信号通路 >> 其他 >> 其他

研究领域 >> 代谢疾病

[参考文献]

[1]. DiNicolantonio, J.J., Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol, 2012. 8(5): p. 707-28.

[2]. Oyama, M.A., et al., Use of the loop diuretic torsemide in three dogs with advanced heart failure. J Vet Cardiol, 2011. 13(4): p. 287-92.

[相关活性小分子]

托拉塞米物理化学性质

[ 密度 ]:
1.3±0.1 g/cm3

[ 熔点 ]:
163-164ºC

[ 分子式 ]:
C₁₆H₂₀N₄O₃S

[ 分子量 ]:
348.420

[ 精确质量 ]:
348.125610

[ PSA ]:
108.57000

[ LogP ]:
3.53

[ 外观性状 ]:
结晶固体

[ 折射率 ]:
1.595

[ 储存条件 ]:
-20°C Freezer

[ 水溶解性 ]:
Soluble

托拉塞米MSDS

详细MSDS(安全技术说明书)

托拉塞米毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: UT7938000

CHEMICAL NAME :: 3-Pyridinesulfonamide, N-(((1-methylethyl)amino)carbonyl)-4-((3-methylphenyl )amino)-

CAS REGISTRY NUMBER :: 56211-40-6

LAST UPDATED :: 199612

DATA ITEMS CITED :: 10

MOLECULAR FORMULA :: C16-H20-N4-O3-S

MOLECULAR WEIGHT :: 348.46

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >5 gm/kg

TOXIC EFFECTS :: Kidney, Ureter, Bladder - urine volume increased

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S975,1994

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >500 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - respiratory depression Kidney, Ureter, Bladder - urine volume increased

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S975,1994

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >5 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: APFRAD Annales Pharmaceutiques Francaises. (SPPIF, B.P.22, F-41353 Vineuil, France) V.1- 1943- Volume(issue)/page/year: 36,369,1978

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >3 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: APFRAD Annales Pharmaceutiques Francaises. (SPPIF, B.P.22, F-41353 Vineuil, France) V.1- 1943- Volume(issue)/page/year: 36,369,1978

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S983,1994 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1825 mg/kg/52W-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - changes in bladder weight Endocrine - changes in adrenal weight Nutritional and Gross Metabolic - weight loss or decreased weight gain

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S1043,1994

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 72800 ug/kg/13W-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, Bladder - other changes in urine composition Endocrine - changes in adrenal weight

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S1005,1994

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 146 mg/kg/52W-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Blood - other changes Nutritional and Gross Metabolic - changes in sodium

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S1071,1994 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 330 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects Reproductive - Specific Developmental Abnormalities - musculoskeletal system

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S1113,1994

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 400 mg/kg

SEX/DURATION :: female 17-21 day(s) after conception lactating female 20 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - physical

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S1143,1994

点击显示

托拉塞米安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H319

[ 警示性声明 ]:
P305 + P351 + P338

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xi: Irritant;

[ 风险声明 (欧洲) ]:
R36

[ 安全声明 (欧洲) ]:
26-37/39

[ 危险品运输编码 ]:
NONH for all modes of transport

[ RTECS号 ]:
UT7938000

[ 海关编码 ]:
2935009090

托拉塞米合成路线

详细合成路线

托拉塞米上下游产品

托拉塞米上游产品

托拉塞米下游产品

托拉塞米海关

[ 海关编码 ]: 2935009090

[ 中文概述 ]:
2935009090 其他磺（酰）胺. 增值税率:17.0% 退税率:9.0% 监管条件:无最惠国关税:6.5% 普通关税:35.0%

[ 申报要素 ]: 品名, 成分含量, 用途

[ Summary ]:
2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%

托拉塞米文献

Determination of torasemide by fluorescence quenching method with some dihalogenated fluorescein dyes as probes.

Spectrochim. Acta. A. Mol. Biomol. Spectrosc. 114 , 547-52, (2013)

A novel fluorescence quenching method for the determination of torasemide (TOR) with some dihalogenated fluorescein dyes as fluorescence probes was developed. In acidulous medium, TOR could interact w...

Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives?

J. Am. Coll. Cardiol. 61(14) , 1549-50, (2013)

Loop diuretics: comparison of torsemide, furosemide, and bumetanide.

Conn. Med. 60(6) , 343-5, (1996)

更多文献

托拉塞米

托拉塞米用途

托拉塞米作用

托拉塞米名称

托拉塞米生物活性

托拉塞米物理化学性质

托拉塞米MSDS

详细MSDS(安全技术说明书)

托拉塞米毒性和生态

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

托拉塞米安全信息

托拉塞米合成路线

详细合成路线

托拉塞米上下游产品

托拉塞米上游产品

托拉塞米下游产品

托拉塞米海关

托拉塞米文献

相关药品：

推荐生产厂家/供应商：

相关化合物